Skip to main content

Advertisement

SpringerLink
Log in

Advances in the management of Guillain-Barré syndrome

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Guillain-Barré syndrome (GBS) is the most common cause of acute paralysis, yet the pathogenesis has still not been fully elucidated and specific evidence-based consensus management guidelines have not been developed. This paper reviews the research of the past year dedicated to determining the pathogenesis of GBS, optimizing current management, and searching for more efficacious treatment alternatives. Several recent studies have investigated whether there are any particular factors that might predict the course of illness and, thereby, dictate the optimal treatment. Proposed evidence-based guidelines for elective intubation, admission to the intensive care unit, and overall management of GBS are summarized. Therapeutic plasma exchange and intravenous immunoglobulin are both treatments that have been shown to have a beneficial effect on the course of GBS. Various modifications of plasmapheresis, as well as other alternative therapies, are currently being investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. O’Leary CP, Willison HJ: The role of anti-glycolipid antibodies in peripheral neuropathies. Curr Opin Neurol 2000, 13:583–588. An excellent review of the reported clinical-serologic associations in Guillain-Barré syndrome.

    Article  PubMed  CAS  Google Scholar 

  2. Press R, Matá S, Lolli F, et al.: Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré Syndrome. J Neurol Sci 2001, 190:41–47.

    Article  PubMed  CAS  Google Scholar 

  3. Van Koningsveld R, Schmitz PI, Ang CW, et al.: Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 2002, 58:610–614. An interesting look at preceding infections, antiganglioside antibodies, and other factors that might help in predicting disease severity.

    PubMed  Google Scholar 

  4. Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, vander Meché FG: Mild forms of Guillain-Barré Syndrome in an epidemiologic survey of the Netherlands. Neurology 2000, 54:620–625.

    PubMed  Google Scholar 

  5. Hadden RD, Karch H, Hartung HP, et al.: Preceding infections, immune factors, and outcome in Guillain-Barré Syndrome. Neurology 2001, 56:758–765. A larger study looking for serologic markers to predict clinical patterns as part of the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial (PESGGBST) Group.

    PubMed  CAS  Google Scholar 

  6. Kuwabara S, Mori M, Ogawara K, et al.: Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001, 24:54–58.

    Article  PubMed  CAS  Google Scholar 

  7. Yuki N, Ang CW, Koga M, et al.: Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314–321.

    Article  PubMed  CAS  Google Scholar 

  8. Vander Pol WL, vanden Berg LH, Scheepers RH, et al.: IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology 2000, 54:1661–1665. An intriguing small study on how genetics plays a role in the immune response.

    PubMed  Google Scholar 

  9. Govoni V, Granieri E: Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 2001, 14:605–613.

    Article  PubMed  CAS  Google Scholar 

  10. Koga M, Yuki N, Hirata K: Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand 2001, 103:278–287.

    Article  PubMed  CAS  Google Scholar 

  11. Newton-John H: Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust 1985, 142:444–445.

    PubMed  CAS  Google Scholar 

  12. Chevrolet JC, Deléamont P: Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis 1991, 144:814–818.

    PubMed  CAS  Google Scholar 

  13. Lawn ND, Fletcher DD, Henderson RD, et al.: Anticipating mechanical ventilation in Guillain-Barré Syndrome. Arch Neurol 2001, 58:893–898. An excellent, albeit retrospective, study of the early indicators of subsequent progression to respiratory failure that is readily applicable clinically.

    Article  PubMed  CAS  Google Scholar 

  14. Gaber TA, Kirker SG, Jenner JR: Current practice of prophylactic anticoagulation in Guillain-Barré syndrome. Clin Rehabil 2002, 16:190–193.

    Article  PubMed  CAS  Google Scholar 

  15. Ropper AH, Shahani BT: Pain in Guillain-Barré Syndrome. Arch Neurol 1984, 41:511–514.

    PubMed  CAS  Google Scholar 

  16. Tripathi M, Kaushik S: Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 2000, 28:655–658.

    Article  PubMed  CAS  Google Scholar 

  17. The Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985, 35:1096–1104.

    Google Scholar 

  18. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987, 22:753–761.

    Article  Google Scholar 

  19. vander Meché FG, Shmitz PI, and the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992, 326:1123–1129.

    Article  PubMed  Google Scholar 

  20. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997, 349:225–230.

    Article  Google Scholar 

  21. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997, 41:298–306.

    Article  Google Scholar 

  22. Weinstein RW: Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000, 15:74–128.

    Article  PubMed  CAS  Google Scholar 

  23. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992, 32:94–97.

    Article  Google Scholar 

  24. Raphael JC, Chevret S, Harboun M, et al.: Intravenous immune globulins in patients with Guillain-Barré Syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001, 71:235–238.

    Article  PubMed  CAS  Google Scholar 

  25. Nagpal S, Benstead T, Shumak K, et al.: Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apheresis 1999, 14:107–113.

    Article  PubMed  CAS  Google Scholar 

  26. Ropper AH, Albers JW, Addison R: Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988, 45:314–315.

    PubMed  CAS  Google Scholar 

  27. Castro LH, Ropper AH: Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993, 43:1034–1036.

    PubMed  CAS  Google Scholar 

  28. Kleyweg RP, van der Meché FG: Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991, 54:957–960.

    Article  PubMed  CAS  Google Scholar 

  29. Irani DN, Cornblath DR, Chaudry V, et al.: Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993, 43:872–875.

    PubMed  CAS  Google Scholar 

  30. Kleyweg RP, vander Meché FG, Meulstee J: Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988, 38:1639–1641.

    PubMed  CAS  Google Scholar 

  31. Jackson MC, Godwin-Austen RB, Whiteley AM: High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol 1993, 240:51–53.

    Article  PubMed  CAS  Google Scholar 

  32. Osterman PO, Fagius J, SÄfwenberg K, Wikström B: Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 1988, 77:273–277.

    PubMed  CAS  Google Scholar 

  33. Green DM, Ropper AH: Mild Guillain-Barré syndrome. Arch Neurol 2001, 58:1098–1101.

    Article  PubMed  CAS  Google Scholar 

  34. Mori M, Kuwabara S, Fukutake T, et al.: Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001, 56:1104–1106.

    PubMed  CAS  Google Scholar 

  35. Oh SJ, LaGanke C, Claussen GC: Sensory Guillain-Barré syndrome. Neurology 2001, 56:82–86.

    Article  PubMed  CAS  Google Scholar 

  36. Chowdhury D, Arora A: Axonal Guillain-Barré syndrome: a critical review. Acta Neurol Scand 2001, 103:267–277. An excellent overview of axonal Guillain-Barré syndrome.

    Article  PubMed  CAS  Google Scholar 

  37. Hartung HP, Kieseier BC, Kiefer R: Progress in Guillain-Barré syndrome. Curr Opin Neurol 14:597–604.

  38. Wollinsky KH, Hülser PJ, Brinkmeier H, et al.: CSF filtration is an effective treatment of Guillain-Barré Syndrome: results of a randomized clinical trial. Neurology 2001, 57:774–779. A novel, potential treatment technique that should be investigated further in a larger study in combination with either therapeutic plasma exchange or intravenous immunoglobulin.

    PubMed  CAS  Google Scholar 

  39. Feasby TE, Hartung HP: Drain the roots: a new treatment for Guillain-Barré syndrome? Neurology 2001, 57:753–754.

    PubMed  CAS  Google Scholar 

  40. Haupt WF, Birkmann C, vander Ven C, Pawlik G: Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome. Ther Apheresis 2000, 4:198–200.

    Article  CAS  Google Scholar 

  41. Diener HC, Haupt WF, Kloss TM, et al.: A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 2001, 46:107–109.

    Article  PubMed  CAS  Google Scholar 

  42. Lyu RK, Chen WH, Hsieh ST: Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome. Ther Apheresis 2002, 6:163–166.

    Article  Google Scholar 

  43. Creange A, Chazaud B, Plonquet A, et al.: IFN-b decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré Syndrome. Neurology 2001, 57:1704–1706.

    PubMed  CAS  Google Scholar 

  44. Bensa S, Hadden RD, Hahn A, et al.: Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol 2000, 7:423–426.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Queen’s Medical Center, Neuroscience Institute, 1301 Punchbowl Street, 96813, Honolulu, HI, USA

    Deborah M. Green MD

Authors
  1. Deborah M. Green MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, D.M. Advances in the management of Guillain-Barré syndrome. Curr Neurol Neurosci Rep 2, 541–548 (2002). https://doi.org/10.1007/s11910-002-0043-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-002-0043-0

Keywords

Search

Navigation